XML 116 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
Schedule of Financial Data for Business Segments
The financial data for the two business segments are as follows ($ amounts in thousands):

 
For the Year Ended
 
For the Period
 
For the Year Ended
 
December 31, 2013
 
September 29, 2012 to
December 31, 2012
 
January 1, 2012 to
September 28, 2012
 
December 31,
2011
 
(Successor)
 
(Successor)
 
(Predecessor)
 
(Predecessor)
Revenues:
 
 
 
 
 
 
 
Par Pharmaceutical

$1,028,418

 

$227,312

 

$743,360



$834,592

Strativa
69,049

 
18,827

 
60,508


91,546

Total revenues

$1,097,467

 

$246,139

 

$803,868

 

$926,138

 
 
 
 
 
 
 
 
Gross margin:
 
 
 
 
 
 
 
Par Pharmaceutical
271,396

 
33,776

 
296,338

 
320,313

Strativa
46,647

 
11,669

 
46,012

 
66,431

Total gross margin

$318,043

 

$45,445

 

$342,350

 

$386,744

 
 
 
 
 
 
 
 
Operating (loss) income:
 
 
 
 
 
 
 
Par Pharmaceutical
(48,082
)
 
(25,938
)
 
116,591


(10,973
)
Strativa
(17,361
)
 
(3,825
)
 
(57,151
)

(39,620
)
Total operating (loss) income

($65,443
)
 

($29,763
)
 

$59,440

 

($50,593
)
Gain (loss) on marketable securities and other investments, net
1,122

 
—


—


237

Gain on bargain purchase
—

 
5,500


—


—

Interest income
87

 
50


424


736

Interest expense
(95,484
)
 
(25,985
)

(9,159
)

(2,676
)
Loss on debt extinguishment
(7,335
)
 
—


—


—

(Benefit) provision for income taxes
(61,182
)
 
(17,682
)

29,447


(5,996
)
(Loss) income from continuing operations

($105,871
)
 

($32,516
)
 

$21,258

 

($46,300
)
Schedule of Total Revenues of Top Selling Products
Total revenues of our top selling products were as follows ($ amounts in thousands):

 
For the Year Ended
 
For the Period
 
For the Year Ended
Product
December 31,
2013
 
September 29, 2012 to
December 31, 2012
 
January 1, 2012 to
September 28, 2012
 
December 31,
2011
 
(Successor)
 
(Successor)
 
(Predecessor)
 
(Predecessor)
Par Pharmaceutical
 
 
 
 
 
 
 
Budesonide (Entocort® EC)

$198,834

 

$36,710



$103,762



$70,016

Propafenone (Rythmol SR®)
70,508

 
19,623


53,825


69,835

Metoprolol succinate ER (Toprol-XL®)
56,670

 
31,287


154,216


250,995

Lamotrigine (Lamictal XR®)
54,577

 
—


—


—

Divalproex (Depakote®)
46,635

 
2,436


9,099


—

Rizatriptan (Maxalt®)
45,598

 
—

 
—

 
—

Bupropion ER (Wellbutrin®)
45,403

 
11,255


34,952


—

Chlorpheniramine/Hydrocodone (Tussionex®)
33,518

 
17,403


30,706


39,481

Modafinil (Provigil®)
27,688

 
16,956


88,831


—

Diltiazem (Cardizem® CD)
27,212

 
3,702


—


—

Other (1)
390,346

 
79,789


249,383


374,288

Other product related revenues (2)
31,429

 
8,151


18,586


29,977

Total Par Pharmaceutical Revenues

$1,028,418

 

$227,312

 

$743,360

 

$834,592

 
 
 
 
 
 
 
 
Strativa
 
 
 
 
 
 
 
Megace® ES

$39,510

 

$10,910

 

$38,322



$58,172

Nascobal® Nasal Spray
26,864

 
7,138

 
17,571


21,399

Other
(910
)
 
130

 
130


3,309

Other product related revenues (2)
3,585

 
649

 
4,485


8,666

Total Strativa Revenues

$69,049

 

$18,827

 

$60,508

 

$91,546


(1)
The further detailing of revenues of the other approximately 50 generic drugs was not considered significant to the overall disclosure due to the lower volume of revenues associated with each of these generic products. No single product in the other category was significant to total generic revenues for the year ended December 31, 2013 (Successor), the period from September 29, 2012 to December 31, 2012 (Successor) or for the period from January 1, 2012 to September 28, 2012 (Predecessor) or for the year ended December 31, 2011 (Predecessor).

(2)
Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.